Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01473459|
Recruitment Status : Unknown
Verified April 2012 by Hillel Yaffe Medical Center.
Recruitment status was: Not yet recruiting
First Posted : November 17, 2011
Last Update Posted : April 26, 2012
|Condition or disease||Intervention/treatment|
|Obese Infertility Polycystic Ovary Syndrome||Procedure: IVM (In Vitro Maturation) Treatment Procedure: IVF (In Vitro Fertilization) Antagonist Protocol|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||January 2013|
|Estimated Study Completion Date :||January 2013|
|Active Comparator: IVM Treatment||
Procedure: IVM (In Vitro Maturation) Treatment
There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
Other Name: IVM
|Active Comparator: Antagonist Protocol||
Procedure: IVF (In Vitro Fertilization) Antagonist Protocol
The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
Other Name: IVF - antagonist protocol
- Fertility results [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01473459
|Contact: Tal Shavit, MDfirstname.lastname@example.org|
|Hillel Yaffe Medical Center|
|Hadera, Israel, 38100|
|Principal Investigator:||Tal Shavit, M.D||IVF unit Hillel-Yaffe medical Center|